EMD Serono Appoints Scott Filosi As Senior Vice President Of Managed Markets

ROCKLAND, Mass., Sept. 9, 2015 /PRNewswire/ -- EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced today the appointment of Scott Filosi as Senior Vice President of Managed Markets. Filosi brings extensive specialty pharmaceutical experience with a focus on managed markets, global business development and market access for biologics. He has led national and regional accounts teams including federal, field reimbursement, contracting and health outcomes.

As Senior Vice President of Managed Markets, Filosi will be responsible for developing and executing Managed Markets marketing, sales, and contracting strategies to ensure optimal market access and pull through for EMD Serono products for patients, as well as reimbursement strategies for the oncology portfolio. He is also responsible for leading specialty pharmacy patient adherence and retention programs.

"Mr. Filosi brings to us a successful track record of driving operational growth and performance for mid-sized specialty pharmaceutical market access teams," said Gary Zieziula, Chief Commercial Officer of EMD Serono. "He's well-positioned to lead a strong managed markets team, continuing to drive successful strategies for our specialty care portfolio which will help us deliver our medicines effectively to patients."

Prior to joining EMD Serono, Filosi was the Head of U.S. Market Access and Pricing and the Head of Established Brands in the U.S., and led business operations for Canada and Mexico at UCB Pharma. In this role, he had full Profit and Loss (P&L) responsibility for the established brands and led contracting, access, distribution, reimbursement, access strategy, health outcomes and channel forecasting. 

Previous to UCB, Filosi was Vice President of Global Business Development at i3 Innovus where he led the U.S. and EU business development model design and implementation for health outcomes. Prior to joining i3 Innovus, Filosi spent six years with Boehringer Ingelheim and 13 years with Johnson & Johnson in a variety of commercial and sales roles. 

Filosi holds a B.S. in Marketing and Business Administration from University of Massachusetts.

About EMD Serono

EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is a leading U.S. biopharma company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.   

Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials and generated sales of 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

Cory Tromblee
Phone: 781.681.2393

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emd-serono-appoints-scott-filosi-as-senior-vice-president-of-managed-markets-300139893.html

SOURCE EMD Serono

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.